美通社

2024-09-28 09:11

Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"

SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expansion. The Blue Book also offers a multi-faceted exploration of the development trends and value orientation of Chinese biopharmaceutical global expansion, and aiming to set a broad frame of the internationalization for Chinese biopharmaceutical industry. (To read the Blue Book, go here:https://hub.frost.com/china-biopharmaceutical-industry-growth/ )

"2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" highlights the following:

  • Market Entry Analysis of Different Countries and Regions worldwide (the United States, European Union, Japan, Southeast Asia, Brazil and Middle East)
  • Motivators for Chinese Biopharmaceuticals' International Expansion (government support, technological advancements, increasing healthcare demand globally, etc.)
  • Analysis of the Current Status and trends of Chinese Pharmaceutical Going Global (active pharmaceutical ingredient (APIs), Generics, Biosimilar and Innovative Drugs)
  • Major Strategies for Chinese innovative drugs going global (Independent Global Expansion, Joint Global Expansion and Leveraging Partnerships for Global Expansion)
  • Case Studies of Pharmaceutical Companies and Service Providers (BeiGene, Henlius, Junshi Bio, Nuliferay, Poly Pharm and Thermo Fisher)

Going Global: A Pivotal Approach for Accelerating and Scaling China's Biopharmaceutical Industry Growth

The vast overseas pharmaceutical markets present substantial demands, making it appealing for Chinese biopharmaceutical companies to expand overseas. Moreover, the pressure from medical insurance negotiations and centralized procurement has driven the domestic pharmaceutical companies to seek overseas opportunities in both product and profit competition. Policies such as the "The 14th Five-Year Plan for the Development of the Pharmaceutical Industry" actively encourage and support the global expansion of Chinese biopharmaceutical companies to explore overseas markets. Meanwhile, China's pharmaceutical industry is entering a phase of innovative advancements, characterized with advanced pharmaceutical R&D capabilities and quality standards, as well as a mature innovation ecosystem. The alignment with international standards has also established a strong foundation for the global expansion of China's pharmaceutical sector. Chinese biopharmaceutical companies have now entered an advanced stage of internationalization, actively participating in global market competition and collaboration.

By "Going Global", Chinese biopharmaceutical companies demonstrate their product competitiveness, R&D capabilities, and commercialization potential, ultimately contributing to an increase in their valuation. The vast overseas markets present substantial demand, enabling Chinese pharmaceutical companies to tap into emerging global markets. This expansion further unlocks domestic pharmaceutical production capacity and helps Chinese enterprises surpass domestic sales limitations, leading to greater commercial returns. Furthermore, the process of going global promotes the continuous strengthening of independent R&D and the integration of industry chain resources, contributing to increased brand value.

Companies with both technical expertise and the ability to expand globally have already achieved substantial success

Currently, the global expansion path of China's biopharmaceutical industry is constantly evolving—from the overseas sale of active pharmaceutical ingredients (APIs), to the export of generic drugs, and now to the globalization of innovative drugs. Biopharmaceutical companies with strong technical expertise and global expansion capabilities have achieved significant success.

In 1992, Hisun Pharmaceutical's tobramycin received its first FDA certification, marking the beginning of Chinese API companies going global. In 2017, Huahai Pharmaceutical's paroxetine capsule became China's first generic drug to successfully challenge a U.S. patent. In 2019, BeiGene's zanubrutinib was the first China-developed anticancer drug to be approved by the FDA as a breakthrough therapy and the first Chinese-developed anticancer drug approved in the U.S. In 2022, Legend Biotech's chimeric antigen receptor T (CAR-T) product Carvykti became the first successful Chinese CAR-T product to go global. The year 2023 saw an explosion of activities, with domestic innovative drugs expanding globally, earning the title of the "First Year of Chinese Innovative Drugs Going Global."

These success stories provide valuable experience and insights for biopharmaceutical companies facing the challenges and opportunities of international markets. In the process of global expansion, attention must be paid to regulation compliance, innovation, and market adaptability. Moreover, service providers involved in many application scenarios have set exemplary benchmarks by offering comprehensive services across various stages, from drug R&D and production to registration, approval, and market entry, thus assisting pharmaceutical companies in successfully entering international markets.

The Blue Book includes BeiGene, Henlius, Junshi Bio, Nuliferay, Poly Pharm and Thermo Fisher as case studies, presenting their business areas, pipeline layouts and technology platforms, along with detailed analysis of their differentiated advantages. Additionally, it outlines the overseas development strategies, international layout situations, practical achievements, and experiences, highlighting their global competitive edges as well as the core values of their products that have already been launched or are planned for international markets.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.

source: Frost & Sullivan

【你點睇?】特朗普當局擬關閉美國國家民主基金會,你認為若其關閉是否可促進全球和平穩定?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
8
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
9
一本萬利 | 2025年的五個「勿」(有片)
10
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
14
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
15
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
16
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
17
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
18
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
19
習近平應約與特朗普通電話,特:冀盡快與習見面
20
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
21
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
22
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
23
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
24
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
25
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
26
特朗普就職 | 特朗普上台後行動列表
27
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
28
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
29
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
30
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老